Table 2.
Average percentages of Ki-67 and nuclear Survivin expression according to ameloblastic histological types and subtypes.
| Histological type | Number of cases | Mean ± SD | |
|---|---|---|---|
| %Ki-67 | %Nuclear Survivin | ||
| Solid/multicystic | 38 | 12.8 ± 10.4 | 0.45 ± 1.3 |
| FSA | 6 | 11.1 ± 6 | — |
| ASA | 10 | 9.9 ± 7.4 | — |
| PSA | 22 | 14.6 ± 14.3 | 0.77 ± 1.7 |
| Unicystic | 72 | 16.4 ± 14.3 | 0.72 ± 1.5 |
| LUA | 8 | 24.1 ± 17.8 | 0.5 ± 1.4 |
| MUA | 24 | 17.1 ± 17.8 | 0.67 ± 1.7 |
| IUA | 40 | 14.5 ± 10.9 | 0.8 ± 1.6 |
FSA: follicular solid/multicystic ameloblastoma, ASA: acanthomatous solid/multicystic ameloblastoma, PSA: plexiform solid/multicystic ameloblastoma, LUA: luminal unicystic ameloblastoma, MUA: mural unicystic ameloblastoma, IUA: intraluminal unicystic ameloblastoma. Kruskal-Wallis test. No statistical significance was observed between Ki-67 and Nuclear Survivin, in subtypes of ameloblastomas.